Background
Phase III trial (DUO-O/ENGOT-ov46/AGO-OVAR 23/GOG-3025) in newly diagnosed advanced (FIGO III/IV) high-grade epithelial ovarian cancer without a tumor BRCA mutation, evaluating addition of durvalumab and olaparib maintenance to standard bevacizumab-based first-line therapy, exploiting potential PARP/checkpoint synergy in HRD-positive tumors.
Interventions and follow up
Arm 1 (control): Paclitaxel/carboplatin + bevacizumab + placebo, then maintenance bevacizumab
Arm 2: Paclitaxel/carboplatin + bevacizumab + durvalumab, then maintenance bevacizumab + durvalumab
Arm 3: Paclitaxel/carboplatin + bevacizumab + durvalumab, then maintenance bevacizumab + durvalumab + olaparib
Primary endpoint: investigator-assessed PFS (Arm 3 vs Arm 1) in HRD-positive and ITT populations
mFollow-up: NR (primary analysis)
Arm 2: Paclitaxel/carboplatin + bevacizumab + durvalumab, then maintenance bevacizumab + durvalumab
Arm 3: Paclitaxel/carboplatin + bevacizumab + durvalumab, then maintenance bevacizumab + durvalumab + olaparib
Primary endpoint: investigator-assessed PFS (Arm 3 vs Arm 1) in HRD-positive and ITT populations
mFollow-up: NR (primary analysis)
Results
mPFS, HRD-positive (Arm 3 vs 1): 37.3 vs 23.0mo (HR 0.49, 95% CI 0.34–0.69, P<.001)
mPFS, ITT (Arm 3 vs 1): 24.2 vs 19.3mo (HR 0.63, 95% CI 0.52–0.76, P<.001)
mPFS, Arm 2 vs 1 (ITT): 20.6 vs 19.3mo (HR 0.87, did not meet significance)
OS: immature at primary analysis
mPFS, ITT (Arm 3 vs 1): 24.2 vs 19.3mo (HR 0.63, 95% CI 0.52–0.76, P<.001)
mPFS, Arm 2 vs 1 (ITT): 20.6 vs 19.3mo (HR 0.87, did not meet significance)
OS: immature at primary analysis
Adverse events
Hematologic (grade ≥3, Arm 3 vs 1): anemia 38% vs 4%, neutropenia 22% vs 14%
Other: hypertension 11% vs 12%, fatigue 8% vs 3%; AE-related discontinuation 27% vs 6%. Toxicity consistent with the known profile of each agent.
Other: hypertension 11% vs 12%, fatigue 8% vs 3%; AE-related discontinuation 27% vs 6%. Toxicity consistent with the known profile of each agent.
Conclusions
Adding durvalumab plus olaparib to bevacizumab-based first-line therapy significantly improved PFS in HRD-positive and ITT non-BRCA-mutated advanced ovarian cancer, establishing a novel quadruplet induction/triplet maintenance regimen.
Key Limitations
Three-arm design isolated the olaparib contribution (Arm 3) but durvalumab-alone (Arm 2) added little, raising questions about the immunotherapy component. Substantial added toxicity and AE-related discontinuation (27%) with the triplet maintenance. OS immature at primary analysis; benefit driven largely by the HRD-positive subset.
Clinical Context
Adds to the first-line maintenance landscape (SOLO-1, PAOLA-1) for non-BRCA HRD-positive disease. The added value of durvalumab over a PARP/bevacizumab maintenance backbone remains debated, and regimen selection weighs HRD status, toxicity burden, and access. Not yet a uniformly adopted standard pending mature OS and regulatory review.